This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
Moderna Coronavirus Vaccine May Not Be Ready Before US Elections
by Zacks Equity Research
Moderna (MRNA) does not expect to apply for an emergency use authorization for its mRNA-based coronavirus before the U.S. presidential election scheduled on Nov 3.
Regeneron Surges on Coronavirus Treatment Development Efforts
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.
The Zacks Analyst Blog Highlights: Uniti Group, Zoom Video, Moderna, Tesla and Apple
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Uniti Group, Zoom Video, Moderna, Tesla and Apple
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
by Zacks Equity Research
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
ETFs To Play The IPO Boom
by Neena Mishra
These ETFs provide diversified exposure to hottest IPOs
CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.
5 Biggest Wall Street Stories of the First Nine Months of 2020
by Sweta Killa
The pandemic has accelerated the digital shift, thus driving the e-commerce boom.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $70.55 in the latest trading session, marking a +1.55% move from the prior day.
Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax
by Zacks Equity Research
Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.
Novavax Begins Phase III Study on Coronavirus Vaccine in the UK
by Zacks Equity Research
Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.
4 Coronavirus Vaccine Makers Now in Phase III as J&J Begins Study
by Kinjel Shah
COVID-19 vaccine candidates of four companies - J&J, Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna - are now in late-stage development.
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $67.89 in the latest trading session, marking a -1.38% move from the prior day.
Novavax Expands Coronavirus Vaccine Manufacturing Deal in India
by Zacks Equity Research
Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.
BioNTech Gets New Funding for Coronavirus Vaccine Development
by Zacks Equity Research
BioNTech (BNTX) receives grant of up to almost $445 million to support development and potential approval of its coronavirus vaccine candidate.
Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.
Pfizer Seeks to Raise Coronavirus Study Enrollment Target
by Zacks Equity Research
Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.
Implied Volatility Surging for Moderna (MRNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
AstraZeneca Resumes UK Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in U.K. resume after the Medicines Health Regulatory Authority confirms that it is safe to do so.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $57.56 in the latest trading session, marking a +1.16% move from the prior day.
Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.